This study aimed to evaluate comprehensive clinical and pathological data, including peripheral blood inflammatory markers, tumor markers, and nutritional indices, to identify predictive biomarkers for advanced gastric cancer patients treated with PD-1/PD-L1 inhibitors. This evidence concerns the gene CD274 and gastric cancer.